Business Standard

Monday, December 23, 2024 | 05:43 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Astrazeneca-Sputnik jabs in combo show a better immune response: RDIF

Preliminary results from Azerbaijan trials have been announced

Photo: Bloomberg
Premium

Photo: Bloomberg

Sohini Das Mumbai
Preliminary results show a combination of AstraZeneca and the first component of Sputnik V demonstrate a high immunogenicity profile in clinical study in Azerbaijan, the Russian Direct Investment Fund (RDIF) claimed on Friday.

Meanwhile, in India, the regulator has green-signalled conducting a study on combining the Covishield (AstraZeneca shot made by Serum Institute of India) and Covaxin (Bharat Biotech’s shot) by Christian Medical College (CMC), Vellore.

Experts feel that mixing of vaccines based on two different platforms could trigger a better immune response in the beneficiary. The mix and match approach, known as heterogeneous prime and boost, has been historically

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in